Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study.

Mikhail M KostikElvira KalashnikovaRinat K RaupovEugenia IsupovaEkaterina GaidarAnton A SolovievVera MasalovaLudmila SnegirevaTatyana KornishinaNatalia AbramovaEvgeny SuspitsinLubov SorokinaMaria KanevaMargarita F DubkoNatalia LubimovaEkaterina KuchuinskayaOlga KalashnikovaVyacheslav G Chasnyk

Published in: Biomedicines (2023)

Rituximab biosimilar BCD020 showed effectiveness in LN, whereas previous non-biologic treatment was insufficiently effective. Randomized controlled trials are required to evaluate the efficacy and safety of rituximab and evaluate the benefits when compared with conventional SLE treatment.

Keyphrases

randomized controlled trial
diffuse large b cell lymphoma
systemic lupus erythematosus
young adults
systematic review
machine learning
rheumatoid arthritis
combination therapy
artificial intelligence
big data
electronic health record
smoking cessation